# Phase 2 Study of EPI-743 for Treatment of Rett Syndrome

> **NCT01822249** · PHASE2 · COMPLETED · sponsor: **Edison Pharmaceuticals Inc** · enrollment: 24 (actual)

## Conditions studied

- Rett Syndrome

## Interventions

- **DRUG:** EPI-743
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01822249
- **Lead sponsor:** Edison Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-12
- **Final completion:** 2014-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01822249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01822249, "Phase 2 Study of EPI-743 for Treatment of Rett Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01822249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*